UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in Amedisys, Inc. (NASDAQ:AMED)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 11.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 101,752 shares of the health services provider's stock after purchasing an additional 10,105 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.31% of Amedisys worth $9,238,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares during the period. KBC Group NV boosted its position in shares of Amedisys by 76.8% in the 4th quarter. KBC Group NV now owns 1,158 shares of the health services provider's stock valued at $105,000 after purchasing an additional 503 shares during the period. Calamos Advisors LLC raised its stake in Amedisys by 22.7% during the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider's stock valued at $44,255,000 after acquiring an additional 90,097 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Amedisys by 0.5% during the 4th quarter. Retirement Systems of Alabama now owns 39,822 shares of the health services provider's stock worth $3,615,000 after buying an additional 181 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Amedisys by 448.3% during the 4th quarter. State of Alaska Department of Revenue now owns 20,737 shares of the health services provider's stock valued at $1,882,000 after buying an additional 16,955 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Up 0.1%

Shares of NASDAQ:AMED traded up $0.08 during midday trading on Wednesday, reaching $94.57. 367,543 shares of the company were exchanged, compared to its average volume of 410,497. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $93.59 and a two-hundred day simple moving average of $91.66. The firm has a market cap of $3.10 billion, a PE ratio of 37.53, a P/E/G ratio of 1.78 and a beta of 0.96.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. As a group, sell-side analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Ratings Changes

AMED has been the topic of several research reports. Stephens reissued an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.